Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BD DIAGNOSTIC SYSTEMS

BD Diagnostics manufactures and markets medical supplies and devices and diagnostic systems that include cellular ana... read more Featured Products: More products

Download Mobile App




Field Performance for Rapid Detection of Influenza Virus Analyzed

By LabMedica International staff writers
Posted on 27 Sep 2016
Clinical differentiation of influenza A virus from infections caused by influenza B virus and the other viruses is unreliable, however effective antiviral treatment is only available for influenza A virus infections and must be administered early in the course of disease to be effective.

Historically, rapid influenza virus antigen diagnostic tests (RIDTs) were simple to perform but were insensitive, particularly for recently introduced strains of influenza A virus and influenza B virus. More...
In contrast, the more recently introduced digital immunoassays (DIAs) have improved analytical performance.

Microbiologist at Medical Faculty of Istanbul University conducted single-blinded cross sectional study nine different family medicine centers in Istanbul, Turkey between 01 November 2014 and 01 May 2015. Nasopharyngeal specimens were collected by the physicians at the time of the initial patient visit, typically within three days of the onset of symptoms. Two specimens were collected, from each patient: one for real-time polymerase chain reaction RT-PCR and one for the point-of-care (POC) test.

The POC test used was the BD Veritor System for Rapid Detection of Flu A + B (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). It is a rapid digital chromatographic immunoassay for the direct, qualitative detection of influenza A and B viral nucleoprotein antigens from nasal and nasopharyngeal swabs of symptomatic patients and differentiates influenza A and B viral antigens from a processed sample using a single device. The RT-PCR results were reported with the analysis of amplification plot in the Light Cycler 480 II (Roche Diagnostics, Mannheim, Germany).

A total of 122 patients out of 238 were positive for influenza by RT-PCR including 42 with influenza A H1N1, 11 with influenza A H3N2, two with influenza A undetermined strains, and 68 with influenza B. One patient’s PCR test was positive for both influenza A and B but the Veritor test was negative for both viruses. The clinical sensitivity and specificity of the Veritor test in all age groups was determined to be 80% and 94%, respectively. Positive predictive value was 93% and the negative one was 81%.

The authors concluded that the field performance of the rapid influenza test, the BD Veritor System for Rapid Detection of Flu A + B, was high and found to be useful with respect to rational antiviral use, avoiding unnecessary antibiotic usage and the management of cases by the family physicians. The study was published on September 9, 2016, in the journal BMC Infectious Diseases.

Related Links:
Istanbul University
Becton, Dickinson and Company
Roche Diagnostics

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.